Arrowhead Research reported $989.46M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 989.46M 676.69M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Ligand Pharmaceuticals USD 451.98M 486K Mar/2026
Merck USD 49.12B 222M Mar/2026
Moderna USD 1.3B 7M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 49.01B 2.02B Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
TG Therapeutics USD 753.56M 499.85M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xencor USD 175.16M 12.58M Mar/2026